

SEQUENCE LISTING

<110> Roche Diagnostics GmbH  
F. Hoffmann-La Roche AG

<120> Secernin-1 as a marker for cancer

<130> 26148 WO

<150> EP09161524

<151> 2009-05-29

<160> 4

<170> PatentIn version 3.5

<210> 1

<211> 414

<212> PRT

<213> Homo sapiens

<400> 1

Met Ala Ala Ala Pro Pro Ser Tyr Cys Phe Val Ala Phe Pro Pro Arg  
1 5 10 15

Ala Lys Asp Gly Leu Val Val Phe Gly Lys Asn Ser Ala Arg Pro Arg  
20 25 30

Asp Glu Val Gln Glu Val Val Tyr Phe Ser Ala Ala Asp His Glu Pro  
35 40 45

Glu Ser Lys Val Glu Cys Thr Tyr Ile Ser Ile Asp Gln Val Pro Arg  
50 55 60

Thr Tyr Ala Ile Met Ile Ser Arg Pro Ala Trp Leu Trp Gly Ala Glu  
65 70 75 80

Met Gly Ala Asn Glu His Gly Val Cys Ile Ala Asn Glu Ala Ile Asn  
85 90 95

Thr Arg Glu Pro Ala Ala Glu Ile Glu Ala Leu Leu Gly Met Asp Leu  
100 105 110

Val Arg Leu Gly Leu Glu Arg Gly Glu Thr Ala Lys Glu Ala Leu Asp  
115 120 125

Val Ile Val Ser Leu Leu Glu Glu His Gly Gln Gly Gly Asn Tyr Phe  
130 135 140

Glu Asp Ala Asn Ser Cys His Ser Phe Gln Ser Ala Tyr Leu Ile Val  
145 150 155 160

Asp Arg Asp Glu Ala Trp Val Leu Glu Thr Ile Gly Lys Tyr Trp Ala  
165 170 175

Ala Glu Lys Val Thr Glu Gly Val Arg Cys Ile Cys Ser Gln Leu Ser  
180 185 190

Leu Thr Thr Lys Met Asp Ala Glu His Pro Glu Leu Arg Ser Tyr Ala  
195 200 205

Gln Ser Gln Gly Trp Trp Thr Gly Glu Gly Glu Phe Asn Phe Ser Glu  
210 215 220

Val Phe Ser Pro Val Glu Asp His Leu Asp Cys Gly Ala Gly Lys Asp  
225 230 235 240

Ser Leu Glu Lys Gln Glu Glu Ser Ile Thr Val Gln Thr Met Met Asn  
245 250 255

Thr Leu Arg Asp Lys Ala Ser Gly Val Cys Ile Asp Ser Glu Phe Phe  
260 265 270

Leu Thr Thr Ala Ser Gly Val Ser Val Leu Pro Gln Asn Arg Ser Ser  
275 280 285

Pro Cys Ile His Tyr Phe Thr Gly Thr Pro Asp Pro Ser Arg Ser Ile  
290 295 300

Phe Lys Pro Phe Ile Phe Val Asp Asp Val Lys Leu Val Pro Lys Thr  
305 310 315 320

Gln Ser Pro Cys Phe Gly Asp Asp Asp Pro Ala Lys Lys Glu Pro Arg  
325 330 335

Phe Gln Glu Lys Pro Asp Arg Arg His Glu Leu Tyr Lys Ala His Glu  
340 345 350

Trp Ala Arg Ala Ile Ile Glu Ser Asp Gln Glu Gln Gly Arg Lys Leu  
355 360 365

Arg Ser Thr Met Leu Glu Leu Glu Lys Gln Gly Leu Glu Ala Met Glu

370

375

380

Glu Ile Leu Thr Ser Ser Glu Pro Leu Asp Pro Ala Glu Val Gly Asp  
385 390 395 400

Leu Phe Tyr Asp Cys Val Asp Thr Glu Ile Lys Phe Phe Lys  
405 410

<210> 2

<211> 14

<212> PRT

<213> Artificial

<220>

<223> Synthesized Peptide Extension

<400> 2

Met Arg Gly Ser His His His His His His Ile Glu Gly Arg  
1 5 10

<210> 3

<211> 96

<212> DNA

<213> Artificial

<220>

<223> Synthesized Forward Primer

<400> 3

acgtgaattc attaaagagg agaaattaac tatgagagga tcgcatcacc atcaccatca 60

cattgaaggc cgtgctgcag ctctccaag ttactg 96

<210> 4

<211> 38

<212> DNA

<213> Artificial

<220>

<223> Synthesized Reverse Primer

<400> 4

acgtaagctt tcattactta aagaacttaa tctccgtg 38